Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization

References

• Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.
   PubMed Web of Science ®Google Scholar
• Leijen S, Burgers SA, Baas P, et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs. 2015;33:201–214.
   PubMed Web of Science ®Google Scholar
• Burris Hr, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Pollera C, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994;5:182–184.
   PubMed Web of Science ®Google Scholar
• Giesing D, Lee H, Daniel KD. Drug delivery systems and methods for treatment of bladder cancer with gemcitabine. Google Patents; 2015.
   Google Scholar
• Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731–2736.
   PubMed Web of Science ®Google Scholar
• Blackstein M, Vogel C, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62:2–8.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Serdjebi C, Peters GJ, et al. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78:1–12.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Xu Y-Z, et al. editors. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3–10.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Searcy CE, et al. editors. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23:3–15.
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Grunewald R, Weeks E, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498.
   PubMed Web of Science ®Google Scholar
• Im MM, Flanagan SA, Ackroyd JJ, et al. Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine. Radiat Res. 2015;183:114–123.
   PubMed Web of Science ®Google Scholar
• Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose–escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15:310–316.
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008;7:703–716.
   PubMed Web of Science ®Google Scholar
• Immordino ML, Brusa P, Rocco F, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release. 2004;100:331–346.
   PubMed Web of Science ®Google Scholar
• Cattel L, Airoldi M, Delprino L, et al. Pharmacokinetic evaluation of gemcitabine and 20, 20-difluorodeoxycytidine-50-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol. 2006;17:(Suppl 5):v142–v1v7.
   PubMed Web of Science ®Google Scholar
• Cosco D, Bulotta A, Ventura M, et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:1009–1020.
   PubMed Web of Science ®Google Scholar
• Paolino D, Cosco D, Racanicchi L, et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release. 2010;144:144–150.
   PubMed Web of Science ®Google Scholar
• Yang F, Jin C, Jiang Y, et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev. 2011;37:633–642.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liu L, Zhang D, et al. Preparation and characterization of gemcitabine liposome injections. Pharmazie. 2012;67:844–847.
   PubMed Web of Science ®Google Scholar
• Yang T, Cui F-D, Choi M-K, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317–326.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269:3198–3204.
   PubMed Web of Science ®Google Scholar
• Cern A, Barenholz Y, Tropsha A, et al. Computer-aided design of liposomal drugs: in silico prediction and experimental validation of drug candidates for liposomal remote loading. J Control Release. 2014;173:125–131.
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Sato Y, et al. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. Int J Pharm. 2016;509:178–187.
   PubMed Web of Science ®Google Scholar
• Fang J, Long L, Maeda H. Enhancement of tumor-targeted delivery of bacteria with nitroglycerin involving augmentation of the EPR effect. Bacterial Therapy of Cancer: Methods Protocols. 2016;1409:9–23.
   Google Scholar
• Xu X, Khan MA, Burgess DJ. Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm. 2012;423:410–418.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res. 2003;13:1–8.
   PubMed Web of Science ®Google Scholar
• Marra M, Salzano G, Leonetti C, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012;30:302–309.
   PubMed Web of Science ®Google Scholar
• Marra M, Salzano G, Leonetti C, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomed Nanotechnol. 2011;7:955–964.
   Google Scholar
• Barenolz Y, Haran G. Method of amphiphatic drug loading in liposomes by pH gradient. The US patent US005, 192,549A; 1993.
   Google Scholar
• Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem. 2004;91:54–69.
   PubMed Web of Science ®Google Scholar
• Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012;12:677–682.
   PubMed Web of Science ®Google Scholar
• Baccino F, Aroasio E, Pani P. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer. 1994;73:253–258.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bradshaw-Pierce EL, Delille A, et al. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci. 2008;97:237–250.
   PubMed Web of Science ®Google Scholar
• Xu L, Anchordoquy TJ. Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm. 2010;7:1311–1317.
   PubMed Web of Science ®Google Scholar
• Torchilin V, Omel'Yanenko V, Klibanov A, et al. Incorporation of hydrophilic protein modified with hydrophobic agent into liposome membrane. Biochim Biophys Acta (BBA)-Biomembranes. 1980;602:511–521.
   PubMed Web of Science ®Google Scholar
• Fatouros DG, Antimisiaris SG. Effect of amphiphilic drugs on the stability and zeta-potential of their liposome formulations: a study with prednisolone, diazepam, and griseofulvin. J Colloid Interface Sci. 2002;251:271–277.
   PubMed Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of Zeta potential on the properties of nano-drug delivery systems - a review (Part 2). Trop J Pharm Res. 2013;12:265–273.
   Web of Science ®Google Scholar
• Soema PC, Willems G-J, Jiskoot W, et al. Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. Eur J Pharm Biopharm. 2015;94:427–435.
   PubMed Web of Science ®Google Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81–91.
   PubMed Web of Science ®Google Scholar
• Beck-Broichsitter M, Rieger M, Reul R, et al. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur J Pharm Biopharm. 2013;84:106–114.
   PubMed Web of Science ®Google Scholar
• Son YJ, Jang J-S, Cho YW, et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol–chitosan nanoaggregates by EPR effect. J Control Release. 2003;91:135–145.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li N, Zhou G, et al. In vivo antioxidant activity of polysaccharide fraction from Porphyra haitanesis (Rhodephyta) in aging mice. Pharmacol Res. 2003;48:151–155.
   PubMed Web of Science ®Google Scholar
• Liu H-L, Yang H-L, Lin B-C, et al. Toxic effect comparison of three typical sterilization nanoparticles on oxidative stress and immune inflammation response in rats. Toxicol Res. 2015;4:486–493.
   Web of Science ®Google Scholar